Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast

OBJECTIVE--To examine the association between HIV-II infection and tuberculosis. DESIGN--Cross sectional study comparing the prevalence of HIV-I and HIV-II infections in patients with tuberculosis and in blood donors. SETTING--Abidjan, Ivory Coast, west Africa. PATIENTS--2043 consecutive ambulant pa...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Vol. 302; no. 6775; pp. 496 - 499
Main Authors: De Cock, K M, Gnaore, E, Adjorlolo, G, Braun, M M, Lafontaine, M F, Yesso, G, Bretton, G, Coulibaly, I M, Gershy-Damet, G M, Bretton, R
Format: Journal Article
Language:English
Published: England British Medical Journal Publishing Group 02-03-1991
British Medical Association
BMJ Publishing Group LTD
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE--To examine the association between HIV-II infection and tuberculosis. DESIGN--Cross sectional study comparing the prevalence of HIV-I and HIV-II infections in patients with tuberculosis and in blood donors. SETTING--Abidjan, Ivory Coast, west Africa. PATIENTS--2043 consecutive ambulant patients with tuberculosis (confirmed pulmonary, presumed pulmonary, or extrapulmonary) and 2127 volunteer blood donors. MAIN OUTCOME MEASURE--Prevalence of HIV-I and HIV-II infections as assessed by presence of serum antibodies. RESULTS--Overall rates of HIV infection were 40.2% in patients with tuberculosis (26.4% positive for HIV-I, 4.7% for HIV-II, and 9.0% for both); and 10.4% in blood donors (7.2% positive for HIV-I, 1.9% for HIV-II, and 1.3% for both). HIV-II infection was significantly more common in patients with all types of tuberculosis than in blood donors (97/2043, 4.7% v 40/2127, 1.9%; odds ratio 3.8%, 95% confidence interval 2.6 to 5.6). CONCLUSION--Both HIV-I and HIV-II infections are associated with tuberculosis in Abidjan. 35% of adult tuberculosis in Abidjan is attributable to HIV infection and 4% specifically to HIV-II.
Bibliography:local:bmj;302/6775/496
istex:EE18F6CA717328CEFFDEEA2BD3D4352D97A9D61D
ark:/67375/NVC-BQR5J250-V
PMID:1849431
href:bmj-302-496.pdf
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0959-8138
1468-5833
1756-1833
DOI:10.1136/bmj.302.6775.496